News

The HORIZON project ACCEND Scale Up Accelerator call: last day for applicants

Published on | 4 months ago

Programmes
Culture and society Climate, Energy, Mobility EIC

OASC (Open & Agile Smart Cities & Communities) is a partner in the ACCEND project, a Europe-wide project building the foundations for a stronger, more connected deep tech scaleup scene.

If you're developing solutions for Smart Cities, Net Zero Cities or Regenerative Cites, you might be interested in this opportunity to accelerate your growth, access cross-border testbed and scale across Europe with the support of leading innovation partners.

ACCEND helps deep tech scaleups:

strengthen market readiness

access high-quality piloting environments across Europe

build connections with cities and investors

fast-track expansion into new European markets

With the deadline on april 15th you still have a chance to apply: fill out the application form here.

 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1981 articles available search in articles 

Testimonial

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.